<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC4353273/results/search/drug/results.xml">
  <result pre="Canada. NI drugs, oseltamivir (Tamiflu®, Hoffmann-La Roche Ltd, Canada) and" exact="zanamivir" post="(Relenza®, GlaxoSmithKline Inc, Canada), are the antiviral medications to"/>
  <result pre="for both treatment and prevention of influenza, including H3N2 viruses." exact="Amantadine" post="is not to be prescribed due to resistance of"/>
  <result pre="asparagine to aspartic acid substitution at position 122 and a" exact="leucine" post="to serine substitution at position 157) was associated with"/>
  <result pre="as follows: 1. Antiviral drug therapy i. Residents: Oseltamivir or" exact="zanamivir" post="treatment should be administered as soon as the clinical"/>
  <result pre="regimens for adults are oseltamivir 75 mg PO BID or" exact="zanamivir" post="two inhalations BID. The treatment dose for oral oseltamivir"/>
  <result pre="the extremely unlikely that they are residents of a LCTF." exact="Zanamivir" post="is approved for children seven years of age and"/>
  <result pre="prophylactic doses are oseltamivir 75 mg PO once daily or" exact="zanamivir" post="two inhalations once daily for adults. The prophylactic dose"/>
  <result pre="a day for those who weigh more than 40 kg." exact="Zanamivir" post="is approved for children seven years of age and"/>
 </snippets>
</snippetsTree>
